The Cardiology Advisor21h
Cardiovascular Risk in IBD Similar After Treatment With JAK vs TNF Inhibitors
No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.
Why anti-TNF drugs don't work for some kids with Crohn's disease
A study by Michigan Medicine researchers has investigated possible genetic factors for drug efficacy for children with ...
Healio7d
TNF inhibitors do not increase adverse event risk in rheumatoid arthritis-associated ILD
Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with ...
HDAC Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
The Cardiology Advisor3d
TNF Inhibitors Lower Cardiovascular Event Risks in Ankylosing Spondylitis
Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.
Medical Dialogues5d
Younger Psoriasis Patients More Likely to Stop TNFi, Older Patients Face Adverse Events: Study From BADBIR
The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...
AI Drug Repurposing Helps Find Medicine for Rare Disease
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a ...
Pulmonology Advisor13d
Connective Tissue Disease Treatments Affect COVID-19 Hospitalization and Morality
Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
Dermatology Advisor10d
Biologics in Psoriasis, PsA Do Not Increase Cardiovascular Adverse Events Risk
The use of biologics in psoriasis and psoriatic arthritis management is not linked to the risk of cardiovascular or venous thromboembolic events.
Endocrinology Advisor5d
Children with Rheumatic Diseases at Higher Risk for Severe COVID-19 Outcomes
Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.